US Bancorp’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $73.6K | Buy |
847
+257
| +44% | +$15.5K | ﹤0.01% | 2599 |
|
|
2026
Q1 | $23.8K | Sell |
590
-92
| -13% | -$3.44K | ﹤0.01% | 3027 |
|
|
2025
Q4 | $23.7K | Sell |
682
-104
| -13% | -$8.17K | ﹤0.01% | 3014 |
|
|
2025
Q3 | $65.3K | Sell |
786
-7,543
| -91% | -$546K | ﹤0.01% | 2543 |
|
|
2025
Q2 | $611K | Sell |
8,329
-7,149
| -46% | -$518K | ﹤0.01% | 1391 |
|
|
2025
Q1 | $1.77M | Sell |
15,478
-4,205
| -21% | -$256K | ﹤0.01% | 888 |
|
|
2024
Q4 | $992K | Hold |
19,683
| – | – | ﹤0.01% | 1124 |
|
|
2024
Q3 | $911K | Buy |
19,683
+12,177
| +162% | +$433K | ﹤0.01% | 1180 |
|
|
2024
Q2 | $244K | Sell |
7,506
-17,776
| -70% | -$487K | ﹤0.01% | 1885 |
|
|
2024
Q1 | $637K | Buy |
25,282
+24,884
| +6,252% | +$588K | ﹤0.01% | 1350 |
|
|
2023
Q4 | $12.9K | Sell |
398
-30
| -7% | -$824 | ﹤0.01% | 3227 |
|
|
2023
Q3 | $11.7K | Sell |
428
-194
| -31% | -$5.62K | ﹤0.01% | 3114 |
|
|
2023
Q2 | $13.8K | Buy |
622
+104
| +20% | +$2.39K | ﹤0.01% | 3139 |
|
|
2023
Q1 | $11.2K | Buy |
518
+217
| +72% | +$4.76K | ﹤0.01% | 3237 |
|
|
2022
Q4 | $6.11K | Buy |
301
+62
| +26% | +$1.55K | ﹤0.01% | 3447 |
|
|
2022
Q3 | $6K | Buy |
239
+131
| +121% | +$3.5K | ﹤0.01% | 3527 |
|
|
2022
Q2 | $2K | Buy |
108
+39
| +57% | +$850 | ﹤0.01% | 3809 |
|
|
2022
Q1 | $1K | Buy |
+69
| New | +$1.47K | ﹤0.01% | 3924 |
|
|
2021
Q2 | – | Sell |
-81
| Closed | -$2K | – | 4010 |
|
|
2021
Q1 | $2K | Buy |
+81
| New | +$2.16K | ﹤0.01% | 3685 |
|
|
2020
Q4 | – | Sell |
-172
| Closed | -$3K | – | 3774 |
|
|
2020
Q3 | $3K | Sell |
172
-179
| -51% | -$2.85K | ﹤0.01% | 3402 |
|
|
2020
Q2 | $6K | Buy |
351
+172
| +96% | +$2.42K | ﹤0.01% | 3236 |
|
|
2020
Q1 | $2K | Hold |
179
| – | – | ﹤0.01% | 3442 |
|
|
2019
Q4 | $2K | Hold |
179
| – | – | ﹤0.01% | 3460 |
|
|
2019
Q3 | $3K | Hold |
179
| – | – | ﹤0.01% | 3334 |
|
|
2019
Q2 | $2K | Buy |
+179
| New | +$1.99K | ﹤0.01% | 3435 |
|
|
2019
Q1 | – | Sell |
-188
| Closed | -$3K | – | 3582 |
|
|
2018
Q4 | $3K | Buy |
188
+99
| +111% | +$1.31K | ﹤0.01% | 3311 |
|
|
2018
Q3 | $1K | Buy |
+89
| New | +$1.24K | ﹤0.01% | 3552 |
|
|
2018
Q2 | – | Sell |
-4,648
| Closed | -$76K | – | 3614 |
|
|
2018
Q1 | $76K | Sell |
4,648
-1,851
| -28% | -$34.3K | ﹤0.01% | 2382 |
|
|
2017
Q4 | $117K | Buy |
6,499
+142
| +2% | +$2.57K | ﹤0.01% | 2177 |
|
|
2017
Q3 | $123K | Buy |
6,357
+4,648
| +272% | +$69.3K | ﹤0.01% | 2120 |
|
|
2017
Q2 | $20K | Buy |
+1,709
| New | +$18.6K | ﹤0.01% | 2876 |
|
Other funds holding CORT
ISL
PA
US Bancorp's CORT Position: Q2 2026 in Review
US Bancorp increased its Corcept Therapeutics (CORT) stake by 44% in Q2 2026, buying an estimated $15.5K and bringing the position to 847 shares worth $73.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2599.
US Bancorp first reported a position in CORT in Q2 2017 and has held it in 31 quarters since. The position peaked at $1.77M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.
- US Bancorp held 847 shares of Corcept Therapeutics worth $73.6K as of Q2 2026.
- US Bancorp bought 257 Corcept Therapeutics shares in Q2 2026, an estimated $15.5K.
- Corcept Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2599 holding.
- US Bancorp first reported a position in Corcept Therapeutics in Q2 2017 and has held it in 31 quarters since.
- US Bancorp's Corcept Therapeutics position peaked at $1.77M in Q1 2025.
- 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.